QUIZ: Test Your Oraqix® Non-injectable Anesthesia Knowledge!

Test Your Oraqix® Non-injectable Anesthesia Knowledge!

Disclosure: We value transparency at Today’s RDH. This quiz is sponsored content from Dentsply Sirona Preventive as part of our sponsored partner program.

Take this quiz on Oraqix® non-injectable anesthesia and enter to win a box of Oraqix®, plus an Oraqix® dispenser from Dentsply Sirona! Oraqix, a combination of lidocaine and prilocaine, is uniquely combined with a patented, thermosetting system to deliver pain relief where it’s needed. Combining both of these amides into a single treatment provides dual benefits that are important for creating an appropriate anesthetizing effect - fast onset and a duration that should be long enough to work for the entire treatment.

Learn more about Oraqix® here.

Now let's test your Oraqix® knowledge!

Oraqix® is a non-injectable anesthesia containing which two anesthetics?

1. Prilocaine and mepivicaine
2. Articaine and lidocaine
3. Mepivicaine and articaine
4. Lidocaine and prilocaine

Oraqix® non-injectable anesthetic gel contains 2.5% lidocaine and 2.5% prilocaine in a eutectic mixture. A eutectic mixture is a mixture of two or more components which usually do not interact to form a new chemical compound but, at certain ratios, inhibit the crystallization process of one another resulting in a system having a lower melting point than either of the components. The eutectic mixture of Oraqix® has a melting point below room temperature, therefore both local anesthetics exist as liquid oils rather than as crystals. Oraqix® contains poloxamer excipients, which show reversible temperature-dependent gelation. Together with the lidocaine-prilocaine 1:1 mixture, the poloxamers form a low-viscosity fluid system at room temperature and an elastic gel in the periodontal pocket.1

1. Oraqix FDA Drug Label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021451s007lbl.pdf

Lidocaine and prilocaine belong to the ester class of local anesthetics. Esters primarily metabolize in the liver.

1. Both statements are true
2. Both statements are false
3. The first statement is true, the second statement is false
4. The first statement is false, the second statement is true

Lidocaine and prilocaine belong to the amide class of local anesthetics. “The primary site of biotransformation (metabolism) of amide drugs is the liver. Virtually the entire metabolic process occurs in the liver for lidocaine, mepivacaine, articaine, etidocaine, and bupivacaine. Prilocaine undergoes primary metabolism in the liver, with some also possibly occurring in the lung.”1

1. Malamed, S.F. Handbook of Local Anesthesia. 5th Edition. Mosby, St. Louis, 2004.

The primary action of local anesthetics, such as lidocaine and prilocaine in Oraqix®, is to block potassium channels, thus blocking impulse conduction.

1. True
2. False

“The primary action of local anesthetics in producing a conduction block is to decrease the permeability of the ion channels to sodium ions. Local anesthetics selectively inhibit the peak permeability of sodium, whose value is normally about five to six times greater than the minimum necessary for impulse conduction. Local anesthetics reduce this safety factor, decreasing both the rate of rise of the action potential and its conduction velocity. When the safety factor falls below unity, conduction fails, and nerve block occurs. Local anesthetics produce a very slight, virtually insignificant decrease in potassium conductance through the nerve membrane.”1

1. Malamed, S.F. Handbook of Local Anesthesia. 5th Edition. Mosby, St. Louis, 2004.

Administration instructions for Oraqix® state two applications are required. The first application of Oraqix® gel should be at the gingival margin; the second application is to fill the periodontal pocket with Oraqix® gel.

1. Both statements are true
2. Both statements are false
3. The first statement is true, the second statement is false
4. The first statement is false, the second statement is true

The instructions for Oraqix® state two applications are required. They state, “Apply Oraqix® on the gingival margin around the selected teeth using the blunt-tipped applicator included in the package. Wait 30 seconds, then fill the periodontal pockets with Oraqix® using the blunt-tipped applicator until the gel becomes visible at the gingival margin. Wait another 30 seconds before starting treatment.”1

1. Oraqix FDA Drug Label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021451s007lbl.pdf

After Oraqix® application, waiting longer than 30 seconds to begin treatment enhances the anesthetic effect.

1. True
2. False

“The onset of local anesthetic effect after application of Oraqix® occurs by 30 seconds and a longer waiting time does not enhance the anesthetic effect. Anesthetic effect, as assessed by probing of pocket depths, lasted for about 20 minutes (individual overall range 14 – 31 minutes).”1

1. Oraqix FDA Drug Label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021451s007lbl.pdf

All 5 questions completed!


NOW: Like Dentsply Sirona on Facebook

 

Previous articleAre Patients Being Over-medicated and Are You Paying Attention?
Next articleGeriatric Patients with Poor Dental Health Linked To Respiratory Issues
Dentsply Sirona Preventive
Dentsply Sirona Preventive provides dental professionals with the most comprehensive range of preventive solutions and the support they need to deliver better, safer and faster preventive care. It’s all part of Dentsply Sirona Preventive’s ongoing commitment to prevent disease, improve oral health, and deliver the best possible experience and outcomes for clinicians and patients.

Dentsply Sirona has grown to become a leader in all aspects of preventive care—a company committed to fostering diagnostic and therapeutic excellence through innovation.

The Rinn® brand of imaging accessories helped transform diagnostic procedures.

With the Cavitron® line of ultrasonic scalers and inserts, Dentsply Sirona Preventive introduced the industry’s first stand-alone ultrasonic scaling and air polishing systems.

With proven quality, performance and protection, the Nupro® family of products is leading the way for a more comprehensive approach to preventive hygiene.

And Oraqix® (lidocaine and prilocaine periodontal gel)2.5% / 2.5%, the first and only FDA-approved non-injectable anesthetic, was a major breakthrough in minimizing pain and patient comfort in scaling and root planing.

All over the world, dental professionals rely on Dentsply Sirona Preventive’s scientifically proven and clinically tested products to deliver safer, more comfortable and effective preventive care.